AG
XENE icon

Algert Global’s Xenon Pharmaceuticals XENE Stock Holding History

Algert Global’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3M Buy
419,773
+155,573
+59% +$8.64M 0.3% 46
2026
Q1 		$15.4M Buy
264,200
+141,011
+114% +$6.5M 0.23% 115
2025
Q4 		$5.52M Buy
123,189
+68,934
+127% +$2.9M 0.09% 396
2025
Q3 		$2.18M Sell
54,255
-48,090
-47% -$1.69M 0.04% 656
2025
Q2 		$3.2M Sell
102,345
-21,070
-17% -$687K 0.07% 472
2025
Q1 		$4.14M Sell
123,415
-118,002
-49% -$4.48M 0.1% 336
2024
Q4 		$9.46M Buy
241,417
+21,772
+10% +$900K 0.22% 123
2024
Q3 		$8.65M Buy
219,645
+36,440
+20% +$1.47M 0.23% 107
2024
Q2 		$7.14M Sell
183,205
-810
-0.4% -$32.4K 0.24% 102
2024
Q1 		$7.92M Sell
184,015
-33,305
-15% -$1.53M 0.31% 65
2023
Q4 		$10M Buy
217,320
+88,833
+69% +$3.14M 0.4% 25
2023
Q3 		$4.39M Sell
128,487
-16,390
-11% -$613K 0.21% 144
2023
Q2 		$5.58M Buy
144,877
+106,470
+277% +$4.23M 0.24% 93
2023
Q1 		$1.37M Buy
38,407
+1,991
+5% +$73.6K 0.06% 501
2022
Q4 		$1.44M Sell
36,416
-8,830
-20% -$322K 0.08% 420
2022
Q3 		$1.63M Buy
45,246
+18,842
+71% +$677K 0.1% 344
2022
Q2 		$803K Buy
26,404
+14,330
+119% +$433K 0.06% 567
2022
Q1 		$369K Buy
+12,074
New +$361K 0.02% 911

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Algert Global's XENE Position: Q2 2026 in Review

Algert Global increased its Xenon Pharmaceuticals (XENE) stake by 59% in Q2 2026, buying an estimated $8.64M and bringing the position to 419,773 shares worth $25.3M. The position accounts for 0.3% of the portfolio, ranked #46.

Algert Global first reported a position in XENE in Q1 2022 and has held it in 18 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Algert Global held 419,773 shares of Xenon Pharmaceuticals worth $25.3M as of Q2 2026.
  • Algert Global bought 155,573 Xenon Pharmaceuticals shares in Q2 2026, an estimated $8.64M.
  • Xenon Pharmaceuticals made up 0.3% of Algert Global's portfolio in Q2 2026, its #46 holding.
  • Algert Global first reported a position in Xenon Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.